Entity > Corporation > US > New York City New York > Ardelyx

About Ardelyx

Ardelyx, Inc. is a biopharmaceutical company that discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally.

Ardelyx's Lead Product is IBSRELA® (tenapanor): Tenapanor has completed the Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation and the Phase III clinical trial for the control of serum phosphorus in adult patients with chronic kidney disease (CKD) on dialysis or hyperphosphatemia. IBSRELA (tenapanor) is a prescription medication that works in three ways to treat irritable bowel syndrome with constipation (IBS-C) in adults - it softens stool and speeds bowel movements to improve constipation, it improves leaky gut to reduce abdominal pain, and it reduces the activity of pain-sensing nerves in the gut to reduce abdominal pain.

RDX013 Is Being Developed For Hyperkalemia: Ardelyx is also developing RDX013, a potassium secretagogue, to treat elevated serum potassium, or hyperkalemia, a problem in certain patients with kidney and/or heart disease. Unlike current treatments that bind potassium, RDX013 represents a novel mechanism and targeted therapy that, if successfully approved, could create an entirely new treatment paradigm for patients with hyperkalemia.

Ardelyx Builds Partnerships Globally: The company has agreements with Kyowa Kirin in Japan, Fosun Pharmaceutical Industrial Development Co. Ltd. in China, and Knight Therapeutics, Inc. in Canada for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

Industry: Business & Industrial > Pharmaceuticals & Biotech

More information about Ardelyx